Limited effect of neuritic plaques on neuronal density in the hippocampal CA1 area of Alzheimer patients

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 2, 1998, Pages 77-82

  Salehi, Ahmad ^a   Bakker, Jan M ^a   Mulder, Monique ^b   Swaab, Dick F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Alzheimer disease; ApoE; CA1 area; Hippocampus; Neuritic plaques

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL DEATH; CELL DENSITY; CLINICAL ARTICLE; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; NERVE CELL; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; PRIORITY JOURNAL;

EID: 0032466485     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199806000-00004     Document Type: Article

References (16)

1. Bodian D. A new method for staining nerve fibers and nerve endings in mounted paraffin sections. Anal Rec 1936;65:89-97.
2. Caporaso GL, Gandy SE, Boxbaum JD, Ramabhadran TV, Greegard P. Protein phosphorylation regulates secretion of Alzheimer β/A4 amyloid precursor protein. Proc Natl Acad Sci USA 1992;89:3055-9.
3. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods 1994;53:125-7.
4. Duyckaerts C, Delaère P, Hauw J-J, et al. Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories. A European multicenter study under the auspices of EURAGE. J Neurol Sci 1990;97:295-323.
5. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8.
6. Mann DMA, Neary D, Yates PO, Lincoln J, Snowden JS, Stanworth P. Neurofibrillary pathology and protein synthetic capability in nerve cells in Alzheimer's disease. Neuropathol Appl Neurobiol 1981;7:37-47.
7. Masliah E, Terry RD, Mallory M, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol 1990;137:1293-7.
8. McKhann GD, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
9. Reisberg B, Ferris SH, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
10. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429-37.
11. Salehi A, Ravid R, Gonatas NK, Swaab DF. Decreased activity of the hippocampal neurons in Alzheimer's disease is not related to the presence of the neurofibrillary tangles. J Neuropathol Exp Neurol 1995;54:704-9.
12. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994a;53:438-47.
13. Selkoe DJ. Amyloid protein and Alzheimer's disease. Sci Am 1994b;265: 68-78.
14. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-102.
15. Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:179-96.
16. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994;344:769-72.